Sustained generic pricing pressure
Generic API business faces ongoing pricing erosion, with no improvement expected in the next two quarters, potentially impacting margins.
high · management_commentary
Divi's Laboratories — Q2 FY26
Divi's Laboratories reported a strong Q2 FY26 with PAT of ₹689 crore, up 35% YoY, driven by robust custom synthesis (56% of mix) and stable generic volumes despite pricing press...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Regulatory delays in new project validations
Commercialization of three major capex projects depends on regulatory approvals (EU, US), which could be delayed, pushing revenue contribution beyond 1-2 years.
medium · management_commentaryCompetition from new CDMO entrants
Analyst raised concern about increased competition in custom synthesis from Indian players; management acknowledged but emphasized long-term relationships and non-price factors.
medium · analyst_questionUS tariff impact on raw material costs
Management noted potential cost increases from US tariffs on Chinese suppliers and Russia sanctions, though mitigated by inventory and diversified sourcing.
low · management_commentary